earnings
confidence high
sentiment neutral
materiality 0.65
Atea Q2 net loss $37.2M ($0.44/shr); cash $379.7M; repurchases shares; strategic review ongoing
Atea Pharmaceuticals, Inc.
2025-Q2 EPS
reported -$0.85
vs consensus -$0.42
▼ miss
(-100.8%)
- Net loss of $37.2M ($0.44 diluted EPS) vs $40.5M loss in Q2 2024; R&D expense $32.3M, down $2.4M YoY.
- Cash, equivalents and marketable securities $379.7M at June 30, 2025, down from $454.7M at Dec 31, 2024.
- Board authorized up to $25M share repurchase; 4.6M shares bought at avg $3.01 through June 30.
- Engaged Evercore to evaluate strategic alternatives including partnerships, M&A, or sale of assets.
- Global Phase 3 HCV program (C-BEYOND, C-FORWARD) enrolling on track; 98% SVR12 in Phase 2 per-protocol population.
item 2.02item 9.01